Familial Lipoprotein Lipase Deficiency Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

DelveInsight's Familial Lipoprotein Lipase Deficiency Pipeline Insight, 2022 report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Familial Lipoprotein Lipase Deficiency pipeline landscape

It covers the Familial Lipoprotein Lipase Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Lipoprotein Lipase Deficiency therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Familial Lipoprotein Lipase Deficiency Pipeline Report
• DelveInsight's Familial Lipoprotein Lipase Deficiency Pipeline analysis depicts the space with 7+ active players working to develop 7+ pipeline therapies.
• The Familial Lipoprotein Lipase Deficiency pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
• Familial Lipoprotein Lipase Deficiency Companies include Amryt Pharma, Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, iMetabolic Biopharma, Precision Biosciences, Pfizer, Lipigon Pharmaceuticals, and many others
• Familial Lipoprotein Lipase Deficiency Therapies include IONIS-APOCIII-LRx, ARO-APOC3, cyclosporine, Olezarsen, and many others

To know more about the Familial Lipoprotein Lipase Pipeline report, click here:- https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Lipoprotein Lipase Overview
Familial Lipoprotein Lipase Deficiency (LPLD), also known as Familial Chylomicronemia Syndrome (FCS) is a rare inherited condition, in which the normal breakdown of fats in the body is affected. The condition is inherited in an autosomal recessive pattern. In the past, familial lipoprotein lipase deficiency has also been called hyperlipoproteinemia type I. This deficiency is usually caused by a defect in the LPL gene, which encodes for an enzyme called lipoprotein lipase. A diagnosis of Familial Lipoprotein Lipase Deficiency may be done based upon identification of characteristic symptoms, a detailed patient history, and a thorough clinical evaluation. Blood tests can reveal reduced activity of the lipoprotein lipase enzyme in the plasma. Treatment for Familial Lipoprotein Lipase Deficiency aims to control the symptoms and blood triglyceride levels with a very low-fat diet. Drugs that lower lipid levels in the body are not effective in reducing fat levels.

Familial Lipoprotein Lipase Deficiency Pipeline Insight Report
The Familial Lipoprotein Lipase Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Familial Lipoprotein Lipase Deficiency Emerging Drugs
IONIS-APOCIII-LRx: Ionis Pharmaceuticals
IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. The drug is in Phase III clinical evaluation for the treatment of familial lipoprotein lipase deficiency.

ARO-APOC3: Arrowhead Pharmaceuticals
ARO-APOC3 is a subcutaneously administered RNAi therapeutic that targets apolipoprotein C-III (apoC-III), and reduces VLDL synthesis and assembly, enhances the breakdown of triglyceride rich lipoproteins, and improve clearance of VLDL and chylomicron remnants. The drug is in Phase II clinical studies for the treatment of familial lipoprotein lipase deficiency.

DelveInsight's Familial Lipoprotein Lipase Deficiency Pipeline Report covers around 7+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Download the Familial Lipoprotein Lipase Deficiency Pipeline Report to learn more about the emerging Familial Lipoprotein Lipase Deficiency emerging therapies at @ https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Lipoprotein Lipase Deficiency Pipeline Therapeutic Analysis
There are approx. 7+ key companies which are developing the therapies for Familial Lipoprotein Lipase Deficiency. The companies which have their Familial Lipoprotein Lipase Deficiency drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

Familial Lipoprotein Lipase Deficiency Pipeline report provides insights into:
• All of the companies that are developing therapies for the treatment of Familial Lipoprotein Lipase Deficiency with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Familial Lipoprotein Lipase Deficiency
• Familial Lipoprotein Lipase Deficiency key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Familial Lipoprotein Lipase Deficiency

The Familial Lipoprotein Lipase Deficiency Pipeline Report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Table of Content
1. Introduction
2. Executive Summary
3. Familial Lipoprotein Lipase Deficiency: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Familial Lipoprotein Lipase Deficiency - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. IONIS-APOCIII-LRx: Ionis Pharmaceuticals
9. Mid-Stage Products (Phase II)
10. ARO-APOC3: Arrowhead Pharmaceuticals
11. Early Stage Products (Phase I/II)
12. Drug name: Company name
13. Preclinical/Discovery Stage Products
14. Lipisense: Lipigon Pharmaceuticals
15. Inactive Products
16. Familial Lipoprotein Lipase Deficiency Key Companies
17. Familial Lipoprotein Lipase Deficiency Key Products
18. Familial Lipoprotein Lipase Deficiency- Unmet Needs
19. Familial Lipoprotein Lipase Deficiency- Market Drivers and Barriers
20. Familial Lipoprotein Lipase Deficiency- Future Perspectives and Conclusion
21. Familial Lipoprotein Lipase Deficiency Analyst Views
22. Appendix

Download Sample PDF Report for Familial Lipoprotein Lipase Deficiency clinical trials advancements @ https://www.delveinsight.com/sample-request/familial-lipoprotein-lipase-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.